Andrew Gitkin is a managing director and head of west coast biotechnology investment banking at Piper Jaffray. Andrew has over 20 years of healthcare investment and finance experience. Prior to joining PiperJaffray, he was a senior vice president at Moelis & Co. where he focused on the firm’s life sciences merger and acquisition transactions. Additionally, his previous experience includes Saddle Point Asset Management as a managing member and healthcare portfolio manager, Tavistock Life Sciences as a vice president and CEO of Zephyr Sciences, a biotech company engaged in the in-licensing and development of clinical stage compounds. Andrew was also a senior healthcare analyst in equity research at UBS and SalomonSmithBarney where he was awarded rankings by Institutional Investor and Greenwich Associates. He was honored by Crain’s Business among the top “Forty Under 40.” Andrew holds a bachelor’s degree in business administration from the Goizueta School of Business at Emory University.